Zevra Therapeutics, Inc.
ZVRA
$11.05
$0.252.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 1,322.65% | 134.04% | 98.36% | 474.94% | 81.36% |
| Total Depreciation and Amortization | -77.68% | -78.03% | -75.76% | 5.70% | 5.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58,018.06% | -86.90% | -47.55% | -10,571.18% | 107.52% |
| Change in Net Operating Assets | 240.05% | -87.34% | -874.06% | -406.18% | -4,524.32% |
| Cash from Operations | 174.70% | 133.94% | 125.96% | 81.16% | 49.14% |
| Capital Expenditure | 64.65% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 235.27% | 106.16% | 85.29% | 9,516.28% | -28.07% |
| Cash from Investing | 655.25% | 104.15% | 85.41% | 9,351.16% | -28.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16,053.76% | -- | -- | 100.00% | -- |
| Issuance of Common Stock | 401.41% | 219.85% | -89.92% | 187.71% | 62.61% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3,385.87% | 219.85% | -89.92% | -90.99% | 32.05% |
| Foreign Exchange rate Adjustments | 162.63% | -147.99% | 113.03% | 106.27% | -726.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 833.59% | 139.34% | -54.48% | 388.99% | 1,877.50% |